In a major move to bolster the international supply chain for life-saving biologic treatments, global biotechnology firm Alvotech and contract development and manufacturing organization (CDMO) LOTTE Biologics have announced a long-term strategic partnership. The collaboration focuses on the manufacturing of multiple antibody biosimilar products, aiming to increase the availability of more affordable medical alternatives for patients around the globe.
Under the terms of the agreement, LOTTE Biologics will leverage its state-of-the-art Syracuse facility in New York to produce drug substances for Alvotech’s growing portfolio of biosimilars. This partnership not only strengthens Alvotech’s existing manufacturing network but also significantly expands its footprint within the United States. While the initial agreement centers on specific antibody products, both companies have indicated that the scope of the collaboration has the potential to expand further as demand grows.
The Syracuse facility serves as a cornerstone of this new alliance. Boasting a substantial 40,000-liter bioreactor capacity, the site is fully equipped with on-site process development and rigorous quality control capabilities. The facility’s reputation for operational excellence was recently reinforced when it successfully passed an unannounced U.S. Food and Drug Administration (FDA) inspection with zero observations, signaling a high level of regulatory compliance and manufacturing reliability.
For Alvotech, the partnership is a key component of a broader strategy to scale its development pipeline and ensure a seamless, reliable supply of high-quality biosimilars to international markets. By augmenting its in-house production with LOTTE’s dedicated manufacturing capacity, Alvotech gains the flexibility required to meet the evolving needs of the healthcare sector.
Lisa Graver, CEO of Alvotech, underscored the importance of this synergy. “Our collaboration with LOTTE Biologics will bring additional manufacturing capacity in New York to support patients worldwide, complementing our existing capabilities as we scale our portfolio and prepare for future launches,” Graver stated.
James Park, CEO of LOTTE Biologics, echoed these sentiments, highlighting the complementary strengths of the two organizations. “Alvotech’s expertise in biosimilar development, combined with LOTTE Biologics’ manufacturing capabilities, creates a strong foundation for this collaboration,” Park noted. “We look forward to strategically supporting Alvotech’s growing portfolio and the reliable supply of high-quality, more affordable biologic medicines to patients worldwide.”
The transition to commercial supply remains subject to standard industry milestones, including successful technology transfers, manufacturing qualification, and the receipt of all necessary regulatory approvals. As the biosimilars market continues to mature and demand for cost-effective alternatives to proprietary biologics climbs, this partnership positions both Alvotech and LOTTE Biologics to play a pivotal role in shaping the future of global pharmaceutical manufacturing.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
